Company

Mytos

Rocket Ship Rating

Rocket Ship Rating: 92 out of 100

The Automated CDMO For Regenerative Medicine

Advanced manufacturing
Biotech & therapeutics
Hardware

Status: Operatingas of 2026-09-18
Business model: B2B
Customers: Clinical-Stage companies

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

Powered by Mytos' iDEM™ automation technology, Mytos CDMO enables scalable, consistent production at low cost per dose.

Funding snapshot

Total raised: $19MSum of rounds, as of 2026-09-18Source (opens in a new tab)
Latest round: Series A, $19M2023-11-30

Funding rounds

Series A: $19M2023-11-30, Company stated

Products

Hardware: iDEM™
Web: iDEM™
Web: Mytos CDMO